Spotlighting Efforts to Improve Care Equity, Research Access in MS
Speakers at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 focused their attention on avenues to improve research accessibility for investigators and care access for patients with multiple sclerosis (MS).
Advancing the Clinical Understanding of MS: Emerging Concepts Presented at ACTRIMS 2024
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 opened with discussions on the novel concepts emerging in multiple sclerosis (MS) research, such as the associations between synaptic loss and hypoxia with disease progression.
ACTRIMS 2024 Seeks to Explore and Break Barriers in MS
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) will host its ninth annual meeting in West Palm Beach, Florida, from February 29 to March 2, 2024, to address a plethora of barriers faced by patients and clinicians managing multiple sclerosis (MS).
Hearing Impairment Disproportionately Affects Patients With SCD, Further Studies Required
A cross-sectional comparative study demonstrated the increased prevalence of hearing impairment in children and adults with sickle cell disease (SCD) or sickle cell traits compared with healthy individuals.
Choroid Plexus Indicated in MS Pathology
A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).
Hospitalization, ER, and Medication Discontinuation Rates Still High in PNH
A retrospective analysis surveys the treatment landscape and patterns of patients with paroxysmal nocturnal hemoglobinuria (PNH), illuminating high hospitalization rates and emergency department use despite the availability of multiple treatment options.
Further Studies Required as MS DMT Exposure During Pregnancy Increases
A large-scale, population-based study examined patterns of disease-modifying therapy (DMT) exposure in pregnant patients with MS since 2010, revealing increased occurrences and the need for future studies to examine the impact of newer-developed DMTs.